<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Stem Cell Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Stem Cell Res Ther</journal-id><journal-title-group><journal-title>Stem Cell Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="epub">1757-6512</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">32375892</article-id><article-id pub-id-type="pmc">7201619</article-id><article-id pub-id-type="publisher-id">1679</article-id><article-id pub-id-type="doi">10.1186/s13287-020-01679-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>MiR-153 reduces stem cell-like phenotype and tumor growth of lung adenocarcinoma by targeting Jagged1</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhao</surname><given-names>Guoli</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Zhang</surname><given-names>Yueying</given-names></name><address><email>zhangyueying828@126.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhao</surname><given-names>Zhonghua</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Cai</surname><given-names>Haibo</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Xiaogang</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Tong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Weijun</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Yao</surname><given-names>Chengfang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Zhaopeng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Zhaoxia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Han</surname><given-names>Chen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Hengxiao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Institute of Basic Medicine, The First Affiliated Hospital of Shandong First Medical University, Jinan, 250062 Shandong China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.410587.f</institution-id><institution>School of Medicine and Life Science, </institution><institution>University of Jinan-Shandong Academy of Medical Sciences, </institution></institution-wrap>Jinan, 250062 Shandong China </aff><aff id="Aff3"><label>3</label>Department of Rehabilitation and Physiotherapy, The People&#x02019;s Hospital of Huaiyin, Jinan, 250000 China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.449428.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1797 7280</institution-id><institution>Department of Thoracic Surgery, </institution><institution>The Affiliated First People&#x02019;s Hospital of Jining Medical University, </institution></institution-wrap>Jining, 272011 Shandong China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.452704.0</institution-id><institution>Department of Thoracic Surgery, </institution><institution>The Second Hospital of Shandong University, </institution></institution-wrap>Jinan, 250000 Shandong China </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.452944.a</institution-id><institution>Department of Medical Oncology, </institution><institution>Yantaishan Hospital, </institution></institution-wrap>Yantai, 264000 Shandong China </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>5</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>6</day><month>5</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>11</volume><elocation-id>170</elocation-id><history><date date-type="received"><day>25</day><month>1</month><year>2020</year></date><date date-type="rev-recd"><day>27</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>15</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Cancer stem cells (CSCs) have been proposed to be responsible for tumor recurrence and chemo-resistance. Previous studies suggested that miR-153 played essential roles in lung cancer. However, the molecular mechanism of miR-153 in regulating the stemness of non-small cell lung cancer (NSCLC) remains poorly understood. In this study, we investigated the role of miR-153 in regulation of the stemness of NSCLC.</p></sec><sec><title>Methods</title><p id="Par2">The stemness property of lung stem cancer cells was detected by sphere formation assay, immunofluorescence, and Western blot. Luciferase reporter assay was performed to investigate the direct binding of miR-153 to the 3&#x02032;-UTR of JAG1 mRNA. Animal study was conducted to evaluate the effect of miR-153 on tumor growth in vivo. The clinical relevance of miR-153 in NSCLC was evaluated by Rt-PCR and Kaplan-Meier analysis.</p></sec><sec><title>Results</title><p id="Par3">MiR-153 expression was decreased in lung cancer tissues. Reduced miR-153 expression was associated with lung metastasis and poor overall survival of lung cancer patients. Jagged1, one of the ligands of Notch1, is targeted by miR-153 and inversely correlates with miR-153 in human lung samples. More importantly, we found that miR-153 inhibited stem cell-like phenotype and tumor growth of lung adenocarcinoma through inactivating the Jagged1/Notch1 axis.</p></sec><sec><title>Conclusion</title><p id="Par4">MiR-153 suppresses the stem cell-like phenotypes and tumor growth of lung adenocarcinoma by targeting Jagged1 and provides a potential therapeutic target in lung cancer therapy.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>MiR-153</kwd><kwd>Cancer stem cells (CSC)</kwd><kwd>Lung cancer</kwd><kwd>Jagged1</kwd></kwd-group><funding-group><award-group><funding-source><institution>National Natural Science Foundation of China</institution></funding-source><award-id>81403150</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Yueying</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Natural Science Foundation of Shandong Province of China</institution></funding-source><award-id>ZR2014HL064</award-id><principal-award-recipient><name><surname>Cai</surname><given-names>Haibo</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Traditional Chinese Medical Sciences and Technology of Shandong Province</institution></funding-source><award-id>2015-325</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Yueying</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Key R &#x00026; D project of Shandong Province (Major Key Technologies) </institution></funding-source><award-id>2016ZDJSO7A15</award-id><principal-award-recipient><name><surname>Zhao</surname><given-names>Xiaogang</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Innovation Project of Shandong Academy of Medical Sciences</institution></funding-source><award-id>2019</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Yueying</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par15">Lung cancer is the most common cancer and the leading cause of death in the world [<xref ref-type="bibr" rid="CR1">1</xref>]. Despite continuous efforts to improve therapeutic efficacy, the overall 5-year survival rate for NSCLC is still less than 16% [<xref ref-type="bibr" rid="CR2">2</xref>]. Tumor relapse and development of metastasis remain the major obstacles for improving the overall cancer survival. Cancer stem cells (CSCs) are characterized by the ability of self-renew and resistance to therapy [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>]. A growing body of literature recognizes that the existence of CSCs leads to acquired chemotherapy resistance, tumor relapse, and metastatic spread [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>]. Therefore, strategies targeting CSCs may provide new promising approaches to the treatment of lung cancer.</p><p id="Par16">MicroRNAs (miRNAs) are a class of small, non-coding and evolutionarily conserved RNAs that can play a vital role in suppressing the post-transcriptional expression of a target gene by binding to the 3&#x02032;-untranslated region (3&#x02032;-UTR) of a target messenger RNA (mRNA) [<xref ref-type="bibr" rid="CR11">11</xref>]. There is evidence showing that miRNAs play a crucial role in regulating stem cell function and cancer progression [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. The growing body of evidence suggests that miRNAs are involved in lung CSC self-renewal, metastasis, and chemo-resistance [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>]. Accordingly, Lin et al. [<xref ref-type="bibr" rid="CR18">18</xref>] reported that CD133<sup>+</sup>/CD326<sup>+</sup> cells in the A549 cell line showed greater more than 2-fold changes in expression of 50 miRNAs compared to normal cells and confirmed that miR-29ab, miR-183, miR-17-5p, and miR-127-3P play an essential role in lung cancer. MiR-153 has been shown to play a critical role in various malignancies including lung cancer. However, the effects of miR-153 seem not to be consistent. Some studies suggest that miR-153 functioned as a tumor-suppressive miRNA (TS-miRNA), while other studies suggest that miR-153 functioned as an oncogenic miRNA (oncomiRs). Therefore, the functions and action mechanisms of miR-153 in cancers are not completely clear.</p><p id="Par17">Expression of miR-153 has been reported as significantly decreased in lung cancer tissues in comparison to the adjacent normal tissue [<xref ref-type="bibr" rid="CR19">19</xref>]. MiR-153 can inhibit migration and invasion of human NSCLC by targeting ADAM19; it also can act in this disease as tumor suppressor by inhibiting AKT expression and, consequently, inducing apoptosis of lung cancer cells [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Furthermore, miR-153 has been shown to play an essential role in regulating neural stem cells&#x02019; acquisition of gliogenic competence and in suppressing the osteogenic differentiation of human mesenchymal stem cells [<xref ref-type="bibr" rid="CR21">21</xref>]. However, its role in regulating the lung cancer stem cells has not been explored. To date, there is only one report showing that miR-153 regulates radiosensitivity and stemness of glioma stem cells via reactive oxygen species through Nrf-2/GPx1 pathway [<xref ref-type="bibr" rid="CR22">22</xref>]. However, the underlying mechanism of miR-153 in regulating lung CSCs remains unknown. In this study, we investigated the role and molecular mechanism of miR-153 in regulating human NSCLC stem cells. We found that overexpression of miR-153 suppresses stem cell-like properties and induces xenograft growth delay through suppressing the Jagged1. The study offers some critical insights into the role of miR-153 in regulating lung CSC self-renewal and progression.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Cell culture and treatment</title><p id="Par18">Lung cancer cell line SPC-A-1was obtained from Genechem Technology Co., Ltd. (Shanghai, China). SPC-A-1 cells were cultured with (DMEM)-high glucose (Gibco, USA) supplemented with 10% FBS (TianHang, Biotechnology co, Wuhan, China), penicillin (50&#x02009;U/ml), and streptomycin (50&#x02009;U/ml) (Solarbio, Beijing, China) at 37&#x02009;&#x000b0;C in a humidified atmosphere of 5% CO<sub>2</sub>.The human HEK293T cell line was purchased from ATCC and grown at 37&#x02009;&#x000b0;C in DMEM supplemented with 10% fetal calf serum under 5% of CO2.The cells were recently authenticated by STR profiling and are free from mycoplasma contamination.</p></sec><sec id="Sec4"><title>Transduction</title><p id="Par19">Lentiviral constructs of miR-153 precursor were purchased from System Biosciences (Genechem Co, Shanghai, China). SPC-A-1 cells were transduced with the indicated lentiviruses (MOI&#x02009;=&#x02009;10&#x02013;20) and selected with 1&#x02009;&#x003bc;g/ml puromycin (Genechem Co, Shanghai, China) to generate the stable cell lines.</p></sec><sec id="Sec5"><title>Quantitative RT-PCR</title><p id="Par20">RNA was isolated from cells and tissues using TRIzol reagent (Vazyme biotech co, Nanjing, China), PureLink&#x02122; FFPE RNA Isolation Kit, and mirVana PARIS kit (Life Technology, California, USA). miRNA reverse transcription using 1&#x02009;&#x003bc;g of total RNA from each sample was subjected to cDNA synthesis from miRNA 1st Strand cDNA Synthesis Kit (Vazyme Biotech Co., Nanjing, China). The other RNA reverse transcription was undertaken according to the protocol of HiScript II Q RT SuperMix for qPCR (Vazyme Biotech Co., Nanjing, China). Real-time PCR was performed with SYBR qPCR Mix (Vazyme Biotech Co., Nanjing, China). The thermal-cycling parameters for the PCR were as follows: 95&#x02009;&#x000b0;C for 30&#x02009;s (1&#x02009;cycle), 95&#x02009;&#x000b0;C for 10&#x02009;s followed by 56&#x02009;&#x000b0;C for 30&#x02009;s, and 72&#x02009;&#x000b0;C for 30&#x02009;s (40&#x02009;cycles). U6 and Actin were used as the internal control. Data were calculated using the 2<sup>&#x02212;&#x00394;&#x00394;CT</sup> method. Each experiment was prepared and assayed in triplicate.</p></sec><sec id="Sec6"><title>Tumor sphere formation assay</title><p id="Par21">Transfected SPC-A-1 cells (1&#x02009;&#x000d7;&#x02009;10<sup>3</sup> cells/ml) were seeded per well of a 6-well Corning Ultra-Low attachment plate. Induced cells were grown in DMEM-F12 medium supplemented with EGF (20&#x02009;ng/ml, PEPROTECH, USA), bFGF (20&#x02009;ng/ml, PEPROTECH, USA), and B27 (Gibco, USA). The total number of spheres was counted after 12&#x02009;days [<xref ref-type="bibr" rid="CR23">23</xref>].</p></sec><sec id="Sec7"><title>Immunofluorescence (cells)</title><p id="Par22">Cells were cultured on coverslips, washed in cold PBS, fixed in 95% ethanol for 30&#x02009;min, and permeabilized in 0.3% Triton X-100 (Solarbio, Beijing, China) for 15&#x02009;min. Fixed cells were blocked in PBS containing 5% goat serum (ZSGB, Beijing, China) at 37&#x02009;&#x000b0;C for 1&#x02009;h. Cells were incubated with the primary antibody CD133 (1:1000, #66666-1-lg, Proteintech, Wuhan, China) and Jagged1 (1:400, #bs-1448R, Bioss, Beijing, China) at 4&#x02009;&#x000b0;C overnight. The secondary antibody goat anti-rabbit IgG (Cy3, #GB303, Servicebio, Wuhan, China) was added on cells which were washed three times at 37&#x02009;&#x000b0;C in the dark for 1&#x02009;h. DAPI (Solarbio, Beijing, China) was added on cells for 5&#x02009;min. The fluorescent signal was captured using a TS100 inverted fluorescence microscope (Nikon, Japan).</p></sec><sec id="Sec8"><title>Immunofluorescence(tissue)</title><p id="Par23">Xenograft tumor was made into sections by taking, dehydrating, embedding, and slicing these steps. Slides were removed paraffin and immersed in the distilled water following routine methods. Afterward, antigen retrieval was performed by boiling in sodium citrate buffer for 15&#x02009;min. Slides blocked in PBS containing 5% goat serum at 37&#x02009;&#x000b0;C for 1&#x02009;h. Slides were incubated with the primary antibody CD133 or Jagged1 at 4&#x02009;&#x000b0;C overnight, followed by a conjugated secondary at 37&#x02009;&#x000b0;C in the dark for 1&#x02009;h and DAPI staining. Immunofluorescence was detected by a 3D scanner (3DHISTECH, Hungary).</p></sec><sec id="Sec9"><title>Immunohistochemistry and quantitative image evaluation</title><p id="Par24">For immunohistochemistry, tissue samples were incubated with antibody against proliferating cell nuclear antigen (1:400, #bs-2007R, Bioss, Beijing, China) or Jagged1 (1:400, #bs-1448R, Bioss, Beijing, China) at 4&#x02009;&#x000b0;C overnight. Sections were subsequently incubated with HRP for 60&#x02009;min at 37&#x02009;&#x000b0;C. Coloration was conducted with 3,3-diaminobenzidin (DAB), then kept at room temperature without light for 10&#x02009;min. Staining score was determined as 0: 0&#x02013;5% of staining cells, 1: 6&#x02013;25% of staining cells, 2: 26&#x02013;50% of staining cells, 3: 51&#x02013;75% of staining cells, and 4: &#x0003e;&#x02009;75% of staining cells. Staining intensity was scored as 0&#x02013;1: negative, 2&#x02013;3: weak positive, 4&#x02013;5: intermediate, and 6&#x02013;7: strong positive. The sum of both extent and intensity score was defined as the staining final score [<xref ref-type="bibr" rid="CR24">24</xref>].</p></sec><sec id="Sec10"><title>Western blot</title><p id="Par25">Proteins were extracted using RIPA lysis buffer (Biosharp, Shanghai, China) supplemented with protease inhibitors. The proteins were separated in 10% SDS-PAGE (Beyotime, Shanghai, China) and electrophoretically transferred to PVDF membrane (Milipore, USA). The membranes were incubated with primary antibodies: Actin(1:3000, #bs0061R, Bioss, Beijing, China), Musashi (1:1000, Bioss, Beijing, China), Snail (1:1000, #bs1371R, Bioss, Beijing, China), Notch1 (1:100, #AF5307, Affinity Biosciences, OH, USA), Hes1 (1:200, #BM4488, Boster Biological Technology Co. Ltd., Wuhan, China), and JAG1 (1:500, #bs-1448R, Bioss, Beijing, China) at 4&#x02009;&#x000b0;C overnight. HRP-conjugated secondary antibodies (1:5000, #bs0295M, Bioss, Beijing, China)were used for 1&#x000a0;h at 37&#x02009;&#x000b0;C. The protein bands were observed using ECL reagents (Milipore, USA). Protein immunoreactivity derived from vehicle groups (LV-NC) was normalized to 1.0. Values of LV-miR-153 groups were normalized according to vehicle groups (LV-NC).</p></sec><sec id="Sec11"><title>Luciferase reporter assays</title><p id="Par26">A dual-luciferase reporter assay was used to verify whether Jagged1 was a direct target of miR-153. HEK293T cells were seeded into 96-well plates at 3.75&#x02009;&#x000d7;&#x02009;10<sup>4</sup>cells/well for 24&#x02009;h; pMirGLO 100&#x02009;ng, JAG1-UTR-WT 100&#x02009;ng, JAG1-UTR-MT 100&#x02009;ng, hsa-miR-153-3p mimics 50&#x02009;nM, and NC 50&#x02009;nM were co-transfected into HEK293T cells with Lipofectamine TM 2000 reagent. Cells were harvested 48&#x02009;h after transfection for the measurement of the luciferase activities. The results were expressed as the ratio of firefly luciferase activity to Renilla luciferase activity. The results were from at least three independent experiments. The dual-luciferase reporter assay kit was purchased from Promega (E1910) and the instrument was Thermo Varioskan flash.</p></sec><sec id="Sec12"><title>Bioluminescence assay</title><p id="Par27">SPC-A-1 cells were transduced with the indicated lentiviruses. Transfected SPC-A-1 cells with miR-153 or NC were injected subcutaneously of nude mice. After 25&#x02009;days, the mice were intraperitoneally injected with 10% chloral hydrate, 0.35&#x02009;ml/100&#x02009;g, and exposed to an IVIS 200 imaging system to obtain in vivo images. The total flux of the region of interest (ROI) was analyzed using Living Image&#x000ae; software version 4.5.5 (Xenogen, Hopkinton, MA, USA).</p></sec><sec id="Sec13"><title>Animal study</title><p id="Par28">A total of 10 male 5-week-old BALB/c nude mice were obtained from Beijing SBF Bioscience Co., Ltd. (Beijing, China). The SPC-A-1 cells were resuspended with precooled saline, and the suspension was placed on ice. For tumor studies, 100&#x000a0;&#x003bc;l cell suspension (1&#x02009;&#x000d7;&#x02009;10<sup>6</sup> cells) was injected subcutaneously into the flanks of nude mice. From day 5, tumor volumes were measured with calipers every 2&#x02009;days, and tumor volume was calculated using the formula <italic>V</italic>&#x02009;=&#x02009;1/2 (width<sup>2</sup>&#x02009;&#x000d7;&#x02009;length). After 4&#x000a0;weeks, mice were sacrificed, and tumors were removed and weighed. Tumors were divided into two parts, some of which were fixed in 10% formalin, and the other part was rapidly frozen and retained for RNA and protein research.</p></sec><sec id="Sec14"><title>Tissue specimens</title><p id="Par29">One hundred nineteen NSCLC samples were retrieved from the Second Affiliated Hospital of Shandong University and Jining First People&#x02019;s Hospital. The clinicopathological data were retrospectively collected by reviewing the patients&#x02019; medical charts. Patients enrolled in the study were followed to obtain 5-year survival data. Tumor specimens after surgical resection (<italic>n</italic>&#x02009;=&#x02009;3) were immediately frozen in liquid nitrogen and stored at &#x02212;&#x02009;80&#x02009;&#x000b0;C for mRNA analysis.</p></sec><sec id="Sec15"><title>Statistical analysis</title><p id="Par30">Statistical analysis was performed using SPSS software version 22.0 (IBM SPSS, Armonk, NY, USA). Data were plotted as mean &#x000b1; SD of 3 independent experiments. The significance of the difference between the two groups was determined by Student&#x02019;s <italic>t</italic> test. <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 was considered statistically significant. Overall survival was evaluated by log-rank test. Categorical data were analyzed by the Pearson chi-squared tests. Correlations between miR-153 and Jagged1 expression were analyzed with Pearson&#x02019;s correlation method.</p></sec></sec><sec id="Sec16"><title>Results</title><sec id="Sec17"><title>Enhanced miR-153 expression attenuates the stemness properties of lung cancer cells</title><p id="Par31">To determine whether miR-153 affects the stemness of lung cancer cells, SPC-A-1 cells were transduced with lentiviruses carrying pre-miR-153 (LV-miR-153) or negative control (LV-NC) miRNA. The expression of miR-153 increased by 95-fold in miR-153-overexpressing SPC-A-1 cell lines (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a). Of note, cells overexpressing miR-153 formed fewer and smaller tumor spheres than those transduced with the negative control (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b). Furthermore, both RT-PCR and Western blot analysis indicated that overexpression of miR-153 reduced the expression of snail and musashi-1 (MSI-1) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>c, d). The stem cell marker CD133 was significantly reduced in miR-153-overexpressing cells detected by immunofluorescence analysis (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>e). These results provide evidence that miR153 can suppress the self-renewal capacity of lung cancer cells.
<fig id="Fig1"><label>Fig. 1</label><caption><p>Enhanced miR-153 expression attenuates the stemness properties of lung cancer cells. <bold>a</bold> miR-153 expression in SPC-A-1 cells after miR-153 overexpression was determined by qPCR. <bold>b</bold> Tumor sphere formation capacity of SPC-A-1 cells was analyzed after miR-153 overexpression. Scale bar, 100&#x02009;&#x003bc;m. <bold>c</bold> Stem cell markers (MSI-1 and Snail) expression in control and miR-153-overexpressing cells was analyzed by quantitative PCR. <bold>d</bold> The MSI-1 and snail protein levels in indicated cells were determined by western blot. <bold>e</bold> Stem cell marker CD133 expression was determined by immunofluorescence. Scale bar, 50&#x02009;&#x003bc;m. Data shown are mean &#x000b1; s.d. of three independent experiments. *<italic>P&#x02009;&#x0003c;</italic>&#x000a0;0.05, ***<italic>P&#x02009;&#x0003c;</italic>&#x000a0;0.001 by two tailed Student&#x02019;s <italic>t</italic> test</p></caption><graphic xlink:href="13287_2020_1679_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec18"><title>MiR-153 directly targets Jagged1 and suppresses the Notch activity in lung cancer cells</title><p id="Par32">In order to understand the underlying mechanism by which miR-153 attenuates the CSC phenotypes of cancer cells and to identify target genes of miR-153, we searched for predicted target genes using miRNA target identification web-based tools: PicTar TargetScan and <ext-link ext-link-type="uri" xlink:href="http://miranda.org">miRanda.org</ext-link>. We focused our analysis on the genes that are involved in the regulation of self-renewal and differentiation of stem cells including Notch1, AKT1, NRF2, KLF4, and JAG1. JAG1, one of the Notch ligands, was among these putative miR-153 targets and has been reported to be upregulated in lung cancer [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>], and we evaluated its mRNA concentration in miR-153-overexpressing SPC-A-1 cells and found that it was, indeed, dramatically decreased in these cells (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a). Furthermore, the protein level of Jagged1 was also significantly decreased in SPC-A-1 cells after miR-153 overexpression (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b, f). It is rational that the upregulation of miR-153 in lung cancer might lead to Jagged1 downregulation and suppress the Notch activity in lung cancer cells<bold>.</bold> We also found that the levels of Notch intracellular domain (NICD) was lower in miR-153-overexpressing cells than that in control cells, and the Notch target gene Hes1 was consistently decreased (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b).
<fig id="Fig2"><label>Fig. 2</label><caption><p>miR-153 directly targets Jagged1 and suppresses the Notch activity in lung cancer cells. <bold>a</bold> mRNA expression of indicated genes involved in CSC pathways detected by qPCR. <bold>b</bold> Expression of Jagged1, NCID, and Notch target gene Hes1 were determined by Western blot. <bold>c</bold> Diagram of predicted binding sites of miR-153 on the 3&#x02032;-UTR of Jagged1 gene. <bold>d</bold> Diagram of JAG1 3&#x02032;-UTR wild-type and mutant reporter construct. <bold>e</bold> Luciferase reporter assay was performed in 293&#x02009;T cells with co-transfection of indicated wild-type or mutant 3&#x02032;-UTR constructs and miR-153 mimic. <bold>f</bold> Jagged1 expression was determined by immunofluorescence. Scale bar, 50&#x02009;&#x003bc;m. Data shown are mean &#x000b1; s.d. of three independent experiments. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 by two-tailed Student&#x02019;s <italic>t</italic> test</p></caption><graphic xlink:href="13287_2020_1679_Fig2_HTML" id="MO2"/></fig></p><p id="Par33">In order to further verify whether the miR-153 could directly bind to the 3&#x02032;-UTR of JAG1 (encodes Jagged1) mRNA, we performed a luciferase reporter assay in HEK293T cells co-transfected with vectors harboring wild-type or mutant JAG1 3&#x02032;-UTR and miR-153 mimic (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>c, d). In the case of wild-type JAG1 3&#x02032;-UTR, the luciferase activity was decreased following ectopic miR-153 expression, whereas the mutant constructs nearly rescued the decrease (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>e). Collectively, these data suggest that Jagged1 was negatively regulated by miR-153 in SPC-A-1 cells through its binding to the 3&#x02032;-UTR of JAG1.</p></sec><sec id="Sec19"><title>MiR-153 suppressed Jagged1/Notch pathway and reduced lung carcinoma cell stemness</title><p id="Par34">Jagged1 functions as a ligand for the receptor notch1 that is involved in the regulation of stem cells and cancer [<xref ref-type="bibr" rid="CR27">27</xref>]. Notch activation has been implicated in NSCLC [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Therefore, we further evaluated the effect of miR-153 on the Notch activation in lung cancer cells. SPC-A-1/miR-153 cells were transduced with lentiviruses carrying Jagged1 or control (vector). Jagged1 mRNA expression in indicated cells was determined by qPCR. The expression of Jagged1 increased significantly in Jagged1-overexpressing SPC-A-1/miR-153 cells (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a, b). Moreover, the NICD level and Hes1 expression was rescued by Jagged1 overexpression in miR-153-overexpressing cells (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>b). We further examined whether ectopic expression of Jagged1 can reverse miR-153-induced stemness suppression. The tumor sphere formation capacity of SPC-A-1/miR-153 cells was analyzed after Jagged1 overexpression. SPC-A-1/miR-153 cells with Jagged1 overexpression formed tumor spheres that were comparable with those of negative control (NC) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>c) indicating that Jagged1 overexpression may restore the tumor sphere formation capacity of SPC-A-1/miR-153 cells. Next, we examined the expression of stem cell marker CD133 following transfection with Jagged1 in SPC-A-1/miR-153 cells. Elevated expression of stem cell marker CD133 was observed in Jagged1-overexpressing SPC-A-1/miR-153cells (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>d). These results demonstrate that miR-153 can suppress lung cancer stemness by targeting the Jagged1/Notch pathway in SPC-A-1 cells.
<fig id="Fig3"><label>Fig. 3</label><caption><p>miR-153 suppressed Jagged1/Notch pathway and reduced <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/27196489">lung carcinoma cell</ext-link> stemness. <bold>a</bold> Jagged1 mRNA expression in indicated cells was determined by qPCR. <bold>b</bold> Protein expression of Jagged1, NCID, and Notch target gene Hes1 were determined by Western blot. <bold>c</bold> Tumor sphere formation capacity of SPC-A-1 cells was analyzed after Jagged1 overexpression. <bold>d</bold> Stem cell marker CD133 expression was determined by immunofluorescence. Scale bar, 50&#x02009;&#x003bc;m. Data shown are mean &#x000b1; s.d. of three independent experiments. *<italic>P</italic>&#x000a0;&#x0003c;&#x02009;0.05 by two-tailed Student&#x02019;s <italic>t</italic> test</p></caption><graphic xlink:href="13287_2020_1679_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec20"><title>MiR-153 overexpression inhibits tumor growth in vivo</title><p id="Par35">Next, we evaluated the effect of overexpression of miR-153 on tumor growth in an in vivo model. As shown in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a, the tumor xenografts of the miR-153-overexpressing group grew more slowly than the control group with the average tumor volume in the former group at 25&#x02009;days was markedly lower than in the control group (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a); representative images of subcutaneous tumors evaluated via in vivo bioluminescence assay at 25&#x02009;days after injection is shown in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b. Wet weight of the tumors on that day was also significantly decreased in the miR-153-overexpressing SPC-A-1 cells (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>c). Moreover, the hematoxylin-eosin (HE) stained tumor slices showed extensive necrosis in the miR-153-overexpressing but not the control tumors (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>d). Immunohistochemical staining revealed that expression of the proliferating cell nuclear antigen (PCNA) was also markedly decreased in miR-153-overexpressing tumors (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>d). Furthermore, while the miR-153 expression was increased in miR-153-lentivirus-treated tumors, as expected (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>e), Jagged1 protein expression was profoundly decreased in these cells as detected by immunofluorescence and Western blotting (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>f, g). The expression of the stem cell marker CD133 and MSI1 was markedly decreased in miR-153-lentivirus-treated tumor xenografts when compared with control xenografts (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>h, i). These findings suggest that overexpression of miR-153 contributes to the inhibition of tumorigenicity in vivo by downregulating Jagged1.
<fig id="Fig4"><label>Fig. 4</label><caption><p>miR-153 overexpression inhibits tumor growth in vivo. <bold>a</bold> Subcutaneous tumor model of nude mice at 4&#x02009;weeks after injection (<italic>n</italic>&#x02009;=&#x02009;5 per group). Tumor sizes were measured every 2&#x02009;days. <bold>b</bold> Representative image of subcutaneous tumor evaluated via in vivo bioluminescence assay at 25&#x02009;days after injection. <bold>c</bold> The tumors were collected at 25&#x02009;days after injection and the wet weight of tumor was measured by electronic scale. <bold>d</bold> HE staining and immunohistochemistry analysis of proliferating cell nuclear antigen (PCNA) in tumors from indicated SPC-A-1 cells bearing mice. Scale bar, 100&#x02009;&#x003bc;m. <bold>e</bold> miR-153 expression in tumors from indicated SPC-A-1 cells bearing mice was determined by qPCR. <bold>f</bold> Jagged1 expression was determined by immunofluorescence. Scale bar, 50&#x02009;&#x003bc;m. <bold>g</bold> Jagged1 expression was determined by Western blot. <bold>h</bold> Stem cell marker CD133 expression was determined by immunofluorescence. Scale bar, 50&#x02009;&#x003bc;m. <bold>i</bold> MSI-1 expression was determined by Western blot. Values of Jagged1 or MSI-1 immunoreactivity derived from vehicle groups (LV-NC) was normalized to 1.0. Values of LV-miR-153 groups were normalized according to vehicle groups (LV-NC). Data shown are mean &#x000b1; s.d. of three independent experiments. *<italic>P</italic>&#x000a0;&#x0003c;&#x02009;0.05 by two-tailed Student&#x02019;s <italic>t</italic> test</p></caption><graphic xlink:href="13287_2020_1679_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec21"><title>MiR-153 is a prognostic marker in lung cancer patients</title><p id="Par36">To test the clinical relevance of miR-153 in NSCLC, we evaluated the expression pattern of miR-153 in surgical specimens from 119 pairs of lung cancer surgical specimens and adjacent normal lung tissues by quantitative RT-PCR. The correlations between miR-153 expression and clinical characteristics are presented in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. As shown in Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>a, the expression of miR-153 was lower in the tumor tissue than in the adjacent normal lung tissues (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). Kaplan-Meier analysis indicated that the patients with high miR-153 expression had better overall survival than those with low expression (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>b). We also examined the expression of Jagged1 in these NSCLC specimens. Expression of Jagged 1 was markedly higher in tumors as compared to the adjacent uninvolved lung tissue, as detected by Western blotting and immunohistochemistry (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>c, d). Hypothetical schematic pathway images show that restoration of miR-153 expression may regulate self-renewal capacity and drug resistance by regulating Jagged1 in lung cancer cells (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>e). Of note, chi-squared analysis indicated that miR-153 expression inversely correlated with the expression of Jagged1 (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>; <italic>R</italic>&#x02009;=&#x02009;&#x02212;&#x02009;0.412, <italic>P&#x02009;&#x0003c;</italic>&#x000a0;0.001). These results further support the notion of miR-153 acting as a tumor suppressor by inhibiting Jagged1 expression in NSCLC.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Relationship between miR-153 and clinicopathology features in NSCLC</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Characteristics</th><th rowspan="2">Case number</th><th colspan="2">miR-153 expression</th><th rowspan="2"><italic>P</italic> value</th></tr><tr><th>Low (<italic>n</italic>&#x02009;=&#x02009;48)</th><th>High (<italic>n</italic>&#x02009;=&#x02009;71)</th></tr></thead><tbody><tr><td colspan="5">Age</td></tr><tr><td>&#x02003;&#x0003c;&#x02009;60</td><td>48</td><td>25</td><td>23</td><td>0.765</td></tr><tr><td>&#x02003;&#x02265;&#x02009;60</td><td>71</td><td>35</td><td>36</td><td/></tr><tr><td colspan="5">Gender</td></tr><tr><td>&#x02003;Male</td><td>51</td><td>24</td><td>27</td><td>1.0</td></tr><tr><td>&#x02003;Female</td><td>68</td><td>32</td><td>36</td><td/></tr><tr><td colspan="5">Smoking history</td></tr><tr><td>&#x02003;Yes</td><td>80</td><td>38</td><td>42</td><td>0.901</td></tr><tr><td>&#x02003;No</td><td>39</td><td>19</td><td>20</td><td/></tr><tr><td colspan="5">TNM stage</td></tr><tr><td>&#x02003;I + II</td><td>82</td><td>32</td><td>50</td><td>0.004</td></tr><tr><td>&#x02003;III + IV</td><td>37</td><td>25</td><td>12</td><td/></tr><tr><td colspan="5">Lymph node status</td></tr><tr><td>&#x02003;Yes</td><td>28</td><td>22</td><td>6</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td>&#x02003;No</td><td>91</td><td>31</td><td>60</td><td/></tr><tr><td colspan="5">Distant metastasis</td></tr><tr><td>&#x02003;Yes</td><td>10</td><td>8</td><td>2</td><td>0.082</td></tr><tr><td>&#x02003;No</td><td>109</td><td>56</td><td>53</td><td/></tr><tr><td colspan="5">Histological type</td></tr><tr><td>&#x02003;Adenocarcinoma</td><td>60</td><td>31</td><td>29</td><td>0.784</td></tr><tr><td>&#x02003;Squamous carcinoma</td><td>59</td><td>29</td><td>30</td><td/></tr><tr><td colspan="5">Differentiated degree</td></tr><tr><td>&#x02003;Low/middle</td><td>79</td><td>32</td><td>45</td><td>0.001</td></tr><tr><td>&#x02003;High</td><td>40</td><td>29</td><td>11</td><td/></tr></tbody></table></table-wrap><fig id="Fig5"><label>Fig. 5</label><caption><p>miR-153 is a prognostic marker in lung cancer patients. <bold>a</bold> Relative expression of miR-153 was assessed in adjacent normal (A) and tumor (T) tissues of lung AD patients. The value was normalized to U6. <bold>b</bold> Patients in high-miR-153 expression group had better overall survival (log-rank test, <italic>P</italic>&#x02009;=&#x02009;0.014). <bold>c</bold> Jagged1 protein in adjacent and tumor tissues of lung cancer patients detected by Western blot. <bold>d</bold> Representative images to visualize the staining of Jagged1 in human lung cancer tissue sections. Scale bar, 50&#x02009;&#x003bc;m. <bold>e</bold> Hypothetical schematic pathway image. Data shown are mean &#x000b1; s.d. of three independent experiments. *<italic>P</italic>&#x000a0;&#x0003c;&#x02009;0.05 by two-tailed Student&#x02019;s <italic>t</italic> test</p></caption><graphic xlink:href="13287_2020_1679_Fig5_HTML" id="MO5"/></fig><table-wrap id="Tab2"><label>Table 2</label><caption><p>The correlation of miR-153 and Jagged 1 expression in lung cancer section</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">miR-153</th><th rowspan="2">Cases</th><th colspan="2">Jagged 1</th><th rowspan="2"><italic>R</italic></th><th rowspan="2"><italic>P</italic></th></tr><tr><th>High</th><th>Low</th></tr></thead><tbody><tr><td>High</td><td>48</td><td>13</td><td>35</td><td rowspan="2">&#x02212;&#x02009;0.412</td><td rowspan="2">&#x0003c;&#x02009;0.001</td></tr><tr><td>Low</td><td>71</td><td>49</td><td>22</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec22"><title>Discussion</title><p id="Par37">MiRNAs are a class of critical gene regulators at the post-transcriptional level that are involved in almost every aspect of cancer cell biology [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Some miRNAs involved in stem cell differentiation are involved in modulating CSCs [<xref ref-type="bibr" rid="CR17">17</xref>]. Previous studies suggested that miR-153 plays an essential role in several cancers, including lung cancer [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Furthermore, miR-153 has been shown to play a key role in regulating neural stem cell acquisition of gliogenic competence and in suppressing the osteogenic differentiation of human mesenchymal stem cells [<xref ref-type="bibr" rid="CR21">21</xref>]. Therefore, we speculated that miR-153 might play an essential role in lung cancer stem cells.</p><p id="Par38">To validate this hypothesis, we investigated the role of miR-153 in regulating stemness of lung cancer stem cells. In this study, we found that overexpression of miR-153 suppresses stem cell-like properties of these cells. Overexpression of miR-153 reduced the expression of stem cell markers and tumor sphere formation capacity in SPC-A-1 cells and induced xenograft growth inhibition through suppressing Jagged1. These results suggest that miR-153 may serve as an essential regulator of lung cancer CSCs. Chen et al. found that miR-153 is significantly decreased in lung cancer tissues than in the adjacent tissues and that decreased expression of miR-153 might be a potential unfavorable prognostic factor for patients with NSCLC [<xref ref-type="bibr" rid="CR31">31</xref>]. Moreover, Yuan et al. found that overexpression of miR-153 significantly inhibited the proliferation and migration, promoted the apoptosis of cultured lung cancer cells in vitro, and suppressed the growth of xenograft tumors in vivo [<xref ref-type="bibr" rid="CR19">19</xref>]. Shan et al. found that miR-153 inhibited migration and invasion of human NSCLC by targeting ADAM19 [<xref ref-type="bibr" rid="CR20">20</xref>]. However, the role of miR-153 in regulating stemness of lung cancer stem cells has not been investigated.</p><p id="Par39">CSCs were initially isolated from leukemia and subsequently isolated from solid tumors including brain, breast, prostate, colon, and lung cancer [<xref ref-type="bibr" rid="CR32">32</xref>]. CSC has the characteristics of self-renewal ability, differentiation (asymmetric cell division), high invasion and migration ability, high tumorigenicity, and chemotherapy resistance [<xref ref-type="bibr" rid="CR16">16</xref>]. Therefore, the presence of cancer stem cells is the leading cause of tumor recurrence. At present, flow cytometry, immunomagnetic beads, and tumor spheres induced by serum-free culture have been used to enrich tumor stem cells [<xref ref-type="bibr" rid="CR33">33</xref>]. Here we used tumor spheres to enrich CSCs. Furthermore, we selected CD133, snail, and MSI1 as surface markers of lung CSCs [<xref ref-type="bibr" rid="CR34">34</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref>]. Overexpression of miR-153 reduced the expression of these stem cell markers and the number and the size of tumor spheres. This result was consistent with previous findings that miR-153 regulates the stemness of glioma stem cells as reported by Yang et al. [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par40">In this study, we further showed that the expression of miR-153 was downregulated in tumor tissues significantly, compared with adjacent normal lung tissues. Moreover, the expression of Jagged1 in tumor tissues of lung cancer patients was inversely correlated with the expression of miR-153 (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, <italic>R</italic>&#x02009;=&#x02009;&#x02212;&#x02009;0.412). Importantly, we also demonstrated that miR-153 downregulation is associated with poor prognosis and lung metastasis in NSCLC patients. According to the Kaplan-Meier survival analysis, the patients with low miR-153 expression exhibited more reduced overall survival rates than those with high miR-153 expression. Our result was consistent with previous reports by Chen et al. [<xref ref-type="bibr" rid="CR31">31</xref>].</p><p id="Par41">Target genes of miR-153 have been identified in some tumors [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. MiR-153 plays different roles in different cancers by targeting different genes. Liang et al. reported that miR-153 blocked the paracrine angiopoietin 1 in breast cancer cells [<xref ref-type="bibr" rid="CR37">37</xref>]. Sun et al. found that miR-153 could enhance cell radio sensitivity by targeting BCL2 in human glioma [<xref ref-type="bibr" rid="CR38">38</xref>]. Furthermore, Huang et al. found that miR-153 suppressed IDO1 expression and enhanced CAR-T cell immunotherapy by targeting BCL2 in human glioma [<xref ref-type="bibr" rid="CR39">39</xref>]. In the current study, we further validated that Jagged1 was a novel target gene of miR-153 by the luciferase-based reporter assay in 293&#x02009;T cells. In addition, the protein level of Jagged1 was observed to be significantly decreased in lung cancer cell SPC-A-1 if miR-153 was overexpressed.</p><p id="Par42">The Notch signaling pathway is involved in the regulation of lung cancer stem cells [<xref ref-type="bibr" rid="CR40">40</xref>]. Zhang et al. demonstrated that Notch1 function blockade by &#x003b3;-secretase inhibitor may ablate self-renewing LCSC activity and restore platinum sensitivity in vitro and in vivo [<xref ref-type="bibr" rid="CR41">41</xref>]. A growing body of evidence supports a role for Notch in tumorigenesis, while the importance of Notch ligands in cancer and the upstream control of Notch activation in lung cancer currently remain unclear. Jagged1 is one of the ligands of Notch and participates in the development of human cancer through the Notch signaling pathway [<xref ref-type="bibr" rid="CR42">42</xref>]. Jagged1 has been reported to be upregulated in lung cancers. High expression of Jagged1 is associated with lung cancer progression and poor prognosis [<xref ref-type="bibr" rid="CR43">43</xref>]. However, less is known about the role of Jagged1 in regulating the stemness of lung cancer. The results of the present study indicate that miR-153 could decrease the expression of markers and impair tumor sphere formation activity of lung cancer stem cell by inhibiting Jagged1. Therefore, a novel finding presented in the current study that miR-153 is one of the upstream control factors of Notch activation in lung cancer by targeting Jagged1 and may serve as a potential strategy to eradicate lung cancer stem cells advances our understanding of the role of miR-153 in lung cancer.</p></sec><sec id="Sec23"><title>Conclusions</title><p id="Par43">MiR-153 suppresses the stem-like features of lung cancer cells and inhibits tumor growth by inhibiting the Jagged1/Notch signaling pathway. MiR-153 is one of the upstream control factors of Notch activation in lung cancer by targeting Jagged1 and may serve as a potential strategy to eradicate lung cancer stem cells. These discoveries help us better understand the regulation of the stemness of lung cancer stem cell and provide a novel therapeutic strategy for lung cancer.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>CSCs</term><def><p id="Par5">Cancer stem cells</p></def></def-item><def-item><term>NSCLC</term><def><p id="Par6">Non-small cell lung cancer</p></def></def-item><def-item><term>miRNA</term><def><p id="Par7">MicroRNA</p></def></def-item><def-item><term>mRNA</term><def><p id="Par8">Messenger RNA</p></def></def-item><def-item><term>qRT-PCR</term><def><p id="Par9">Quantitative reverse transcription polymerase chain reaction</p></def></def-item><def-item><term>OS</term><def><p id="Par10">Overall survival</p></def></def-item><def-item><term>qPCR</term><def><p id="Par11">Quantitative PCR</p></def></def-item><def-item><term>TNM</term><def><p id="Par12">Tumor-node-metastasis</p></def></def-item><def-item><term>PCNA</term><def><p id="Par13">Proliferation marker-proliferating cell nuclear antigen</p></def></def-item><def-item><term>HE</term><def><p id="Par14">Hematoxylinand eosin&#x000a0;staining</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Guoli Zhao, Yueying Zhang and Zhonghua Zhao contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We would like to thank Alvin Han, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada, for editing this manuscript.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>YYZ designed and conducted the study and performed animal study. GLZ, HBC, TY, WJC, XGZ, ZPW, ZXW, CFY, YYZ, CH, and HXW performed the experiments. GLZ, ZHZ, HBC, TY, WJC, XGZ, ZPW, ZXW, CFY, and YYZ analyzed the data. GLZ, YYZ, and ZHZ wrote the paper. The authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This research was supported by the following funds: National Natural Science Foundation of China (81403150), Natural Science Foundation of Shandong Province of China (ZR2014HL064), Developmental Project of Traditional Chinese Medical Sciences and Technology of Shandong Province (2015-325), Innovation Project of Shandong Academy of Medical Sciences, and Key R &#x00026; D project of Shandong Province (Major Key Technologies) (2016ZDJSO7A15).</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>Not applicable.</p></notes><notes><title>Ethics approval and consent to participate</title><p id="Par44">This study was approved by the Ethics Committee of The First Affiliated Hospital of Shandong First Medical University. Our institution&#x02019;s committee on human research gave approval for this study, and all participants gave informed consent.</p><p id="Par45">All animal experiments were approved by the Institutional Animal Care and Use Committee of The First Affiliated Hospital of Shandong First Medical University. Treatment of experimental animals followed the internationally recognized 3R principle, that is, replacement, reduction, and refinement of experimental animals and the welfare ethics of experimental animals in accordance with the requirements of the guidelines for ethical review of experimental animal welfare (GB/T 35892-2018) of China.</p></notes><notes><title>Consent for publication</title><p id="Par46">Not applicable.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par47">The authors declare that they have no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer statistics, 2018</article-title><source>CA Cancer J Clin</source><year>2018</year><volume>68</volume><issue>1</issue><fpage>7</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.3322/caac.21442</pub-id><pub-id pub-id-type="pmid">29313949</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Fillmore</surname><given-names>CM</given-names></name><name><surname>Hammerman</surname><given-names>PS</given-names></name><name><surname>Kim</surname><given-names>CF</given-names></name><name><surname>Wong</surname><given-names>KK</given-names></name></person-group><article-title>Non-small-cell lung cancers: a heterogeneous set of diseases</article-title><source>Nat Rev Cancer</source><year>2014</year><volume>14</volume><issue>8</issue><fpage>535</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1038/nrc3775</pub-id><pub-id pub-id-type="pmid">25056707</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Settleman</surname><given-names>J</given-names></name></person-group><article-title>EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer</article-title><source>Oncogene.</source><year>2010</year><volume>29</volume><issue>34</issue><fpage>4741</fpage><lpage>4751</lpage><pub-id pub-id-type="doi">10.1038/onc.2010.215</pub-id><pub-id pub-id-type="pmid">20531305</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacDonagh</surname><given-names>L</given-names></name><name><surname>Gray</surname><given-names>SG</given-names></name><name><surname>Breen</surname><given-names>E</given-names></name><name><surname>Cuffe</surname><given-names>S</given-names></name><name><surname>Finn</surname><given-names>SP</given-names></name><name><surname>O'Byrne</surname><given-names>KJ</given-names></name><name><surname>Barr</surname><given-names>MP</given-names></name></person-group><article-title>Lung cancer stem cells: the root of resistance</article-title><source>Cancer Lett</source><year>2016</year><volume>372</volume><issue>2</issue><fpage>147</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2016.01.012</pub-id><pub-id pub-id-type="pmid">26797015</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>MM</given-names></name><name><surname>Ng</surname><given-names>AV</given-names></name><name><surname>Lam</surname><given-names>S</given-names></name><name><surname>Hung</surname><given-names>JY</given-names></name></person-group><article-title>Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><issue>10</issue><fpage>4827</fpage><lpage>4833</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-3557</pub-id><pub-id pub-id-type="pmid">17510412</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eramo</surname><given-names>A</given-names></name><name><surname>Lotti</surname><given-names>F</given-names></name><name><surname>Sette</surname><given-names>G</given-names></name><name><surname>Pilozzi</surname><given-names>E</given-names></name><name><surname>Biffoni</surname><given-names>M</given-names></name><name><surname>Di Virgilio</surname><given-names>A</given-names></name><name><surname>Conticello</surname><given-names>C</given-names></name><name><surname>Ruco</surname><given-names>L</given-names></name><name><surname>Peschle</surname><given-names>C</given-names></name><name><surname>De Maria</surname><given-names>R</given-names></name></person-group><article-title>Identification and expansion of the tumorigenic lung cancer stem cell population</article-title><source>Cell Death Differ</source><year>2008</year><volume>15</volume><issue>3</issue><fpage>504</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4402283</pub-id><pub-id pub-id-type="pmid">18049477</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vidal</surname><given-names>SJ</given-names></name><name><surname>Rodriguez-Bravo</surname><given-names>V</given-names></name><name><surname>Galsky</surname><given-names>M</given-names></name><name><surname>Cordon-Cardo</surname><given-names>C</given-names></name><name><surname>Domingo-Domenech</surname><given-names>J</given-names></name></person-group><article-title>Targeting cancer stem cells to suppress acquired chemotherapy resistance</article-title><source>Oncogene.</source><year>2014</year><volume>33</volume><issue>36</issue><fpage>4451</fpage><lpage>4463</lpage><pub-id pub-id-type="doi">10.1038/onc.2013.411</pub-id><pub-id pub-id-type="pmid">24096485</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>MF</given-names></name><name><surname>Dick</surname><given-names>JE</given-names></name><name><surname>Dirks</surname><given-names>PB</given-names></name><name><surname>Eaves</surname><given-names>CJ</given-names></name><name><surname>Jamieson</surname><given-names>CH</given-names></name><name><surname>Jones</surname><given-names>DL</given-names></name><name><surname>Visvader</surname><given-names>J</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name><name><surname>Wahl</surname><given-names>GM</given-names></name></person-group><article-title>Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><issue>19</issue><fpage>9339</fpage><lpage>9344</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-3126</pub-id><pub-id pub-id-type="pmid">16990346</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reya</surname><given-names>T</given-names></name><name><surname>Morrison</surname><given-names>SJ</given-names></name><name><surname>Clarke</surname><given-names>MF</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name></person-group><article-title>Stem cells, cancer, and cancer stem cells</article-title><source>Nature.</source><year>2001</year><volume>414</volume><issue>6859</issue><fpage>105</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1038/35102167</pub-id><pub-id pub-id-type="pmid">11689955</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorelik</surname><given-names>E</given-names></name><name><surname>Lokshin</surname><given-names>A</given-names></name><name><surname>Levina</surname><given-names>V</given-names></name></person-group><article-title>Lung cancer stem cells as a target for therapy</article-title><source>Anti Cancer Agents Med Chem</source><year>2010</year><volume>10</volume><issue>2</issue><fpage>164</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.2174/187152010790909308</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group><article-title>MicroRNAs: genomics, biogenesis, mechanism, and function</article-title><source>Cell.</source><year>2004</year><volume>116</volume><issue>2</issue><fpage>281</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(04)00045-5</pub-id><pub-id pub-id-type="pmid">14744438</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shcherbata</surname><given-names>HR</given-names></name><name><surname>Hatfield</surname><given-names>S</given-names></name><name><surname>Ward</surname><given-names>EJ</given-names></name><name><surname>Reynolds</surname><given-names>S</given-names></name><name><surname>Fischer</surname><given-names>KA</given-names></name><name><surname>Ruohola-Baker</surname><given-names>H</given-names></name></person-group><article-title>The MicroRNA pathway plays a regulatory role in stem cell division</article-title><source>Cell Cycle</source><year>2006</year><volume>5</volume><issue>2</issue><fpage>172</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.4161/cc.5.2.2343</pub-id><pub-id pub-id-type="pmid">16357538</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calin</surname><given-names>GA</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name></person-group><article-title>MicroRNA signatures in human cancers</article-title><source>Nat Rev Cancer</source><year>2006</year><volume>6</volume><issue>11</issue><fpage>857</fpage><lpage>866</lpage><pub-id pub-id-type="doi">10.1038/nrc1997</pub-id><pub-id pub-id-type="pmid">17060945</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhuang</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Song</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><etal/></person-group><article-title>miR-127 promotes EMT and stem-like traits in lung cancer through a feed-forward regulatory loop</article-title><source>Oncogene.</source><year>2017</year><volume>36</volume><issue>12</issue><fpage>1631</fpage><lpage>1643</lpage><pub-id pub-id-type="doi">10.1038/onc.2016.332</pub-id><pub-id pub-id-type="pmid">27869168</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Xiang</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Long</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name></person-group><article-title>Targeting the Wnt-regulatory protein CTNNBIP1 by microRNA-214 enhances the stemness and self-renewal of cancer stem-like cells in lung adenocarcinomas</article-title><source>Stem Cells</source><year>2015</year><volume>33</volume><issue>12</issue><fpage>3423</fpage><lpage>3436</lpage><pub-id pub-id-type="doi">10.1002/stem.2188</pub-id><pub-id pub-id-type="pmid">26299367</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Fu</surname><given-names>Q</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Cho</surname><given-names>WC</given-names></name></person-group><article-title>MicroRNA as regulators of cancer stem cells and chemoresistance in colorectal cancer</article-title><source>Curr Cancer Drug Targets</source><year>2016</year><volume>16</volume><issue>9</issue><fpage>738</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.2174/1568009616666151118114759</pub-id><pub-id pub-id-type="pmid">26577538</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garofalo</surname><given-names>M</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name></person-group><article-title>Role of microRNAs in maintaining cancer stem cells</article-title><source>Adv Drug Deliv Rev</source><year>2015</year><volume>81</volume><fpage>53</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2014.11.014</pub-id><pub-id pub-id-type="pmid">25446141</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>JG</given-names></name><name><surname>Wu</surname><given-names>JB</given-names></name><name><surname>Long</surname><given-names>HX</given-names></name><name><surname>Zhu</surname><given-names>CH</given-names></name><name><surname>Xiang</surname><given-names>T</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>ZQ</given-names></name><name><surname>Yao</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Aberrant microRNAs expression in CD133(+)/CD326(+) human lung adenocarcinoma initiating cells from A549</article-title><source>Mol Cells</source><year>2012</year><volume>33</volume><issue>3</issue><fpage>277</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1007/s10059-012-2252-y</pub-id><pub-id pub-id-type="pmid">22349807</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Ju</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Suppression of AKT expression by miR-153 produced anti-tumor activity in lung cancer</article-title><source>Int J Cancer</source><year>2015</year><volume>136</volume><issue>6</issue><fpage>1333</fpage><lpage>1340</lpage><pub-id pub-id-type="doi">10.1002/ijc.29103</pub-id><pub-id pub-id-type="pmid">25066607</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shan</surname><given-names>N</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>D</given-names></name><name><surname>Duan</surname><given-names>C</given-names></name></person-group><article-title>MiR-153 inhibits migration and invasion of human non-small-cell lung cancer by targeting ADAM19</article-title><source>Biochem Biophys Res Commun</source><year>2015</year><volume>456</volume><issue>1</issue><fpage>385</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2014.11.093</pub-id><pub-id pub-id-type="pmid">25475731</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuyama</surname><given-names>J</given-names></name><name><surname>Bunt</surname><given-names>J</given-names></name><name><surname>Richards</surname><given-names>LJ</given-names></name><name><surname>Iwanari</surname><given-names>H</given-names></name><name><surname>Mochizuki</surname><given-names>Y</given-names></name><name><surname>Hamakubo</surname><given-names>T</given-names></name><name><surname>Shimazaki</surname><given-names>T</given-names></name><name><surname>Okano</surname><given-names>H</given-names></name></person-group><article-title>MicroRNA-153 regulates the acquisition of gliogenic competence by neural stem cells</article-title><source>Stem Cell Rep</source><year>2015</year><volume>5</volume><issue>3</issue><fpage>365</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2015.06.006</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name></person-group><article-title>MicroRNA-153/Nrf-2/GPx1 pathway regulates radiosensitivity and stemness of glioma stem cells via reactive oxygen species</article-title><source>Oncotarget.</source><year>2015</year><volume>6</volume><issue>26</issue><fpage>22006</fpage><lpage>22027</lpage><pub-id pub-id-type="pmid">26124081</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>M</given-names></name><name><surname>Cardenas</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Persson</surname><given-names>J</given-names></name><name><surname>Mongan</surname><given-names>NP</given-names></name><name><surname>Grabowska</surname><given-names>A</given-names></name><name><surname>Allegrucci</surname><given-names>C</given-names></name></person-group><article-title>HOXC8 regulates self-renewal, differentiation and transformation of breast cancer stem cells</article-title><source>Mol Cancer</source><year>2017</year><volume>16</volume><issue>1</issue><fpage>38</fpage><pub-id pub-id-type="doi">10.1186/s12943-017-0605-z</pub-id><pub-id pub-id-type="pmid">28202042</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fromowitz</surname><given-names>FB</given-names></name><name><surname>Viola</surname><given-names>MV</given-names></name><name><surname>Chao</surname><given-names>S</given-names></name><name><surname>Oravez</surname><given-names>S</given-names></name><name><surname>Mishriki</surname><given-names>Y</given-names></name><name><surname>Finkel</surname><given-names>G</given-names></name><name><surname>Grimson</surname><given-names>R</given-names></name><name><surname>Lundy</surname><given-names>J</given-names></name></person-group><article-title>ras p21 expression in the progression of breast cancer</article-title><source>Hum Pathol</source><year>1987</year><volume>18</volume><issue>12</issue><fpage>1268</fpage><lpage>1275</lpage><pub-id pub-id-type="doi">10.1016/S0046-8177(87)80412-4</pub-id><pub-id pub-id-type="pmid">3315956</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>JH</given-names></name><name><surname>Deng</surname><given-names>ZH</given-names></name><name><surname>Qu</surname><given-names>XH</given-names></name><name><surname>Jiang</surname><given-names>HY</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group><article-title>Expression and significance of Notch1, Jagged1 and VEGF in human non-small cell lung cancer</article-title><source>Zhong nan da xue xue bao Yi xue ban</source><year>2007</year><volume>32</volume><issue>6</issue><fpage>1031</fpage><lpage>1036</lpage><pub-id pub-id-type="pmid">18182722</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donnem</surname><given-names>T</given-names></name><name><surname>Andersen</surname><given-names>S</given-names></name><name><surname>Al-Shibli</surname><given-names>K</given-names></name><name><surname>Al-Saad</surname><given-names>S</given-names></name><name><surname>Busund</surname><given-names>LT</given-names></name><name><surname>Bremnes</surname><given-names>RM</given-names></name></person-group><article-title>Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer: coexpression of Notch-1 and vascular endothelial growth factor-A predicts poor survival</article-title><source>Cancer.</source><year>2010</year><volume>116</volume><issue>24</issue><fpage>5676</fpage><lpage>5685</lpage><pub-id pub-id-type="doi">10.1002/cncr.25551</pub-id><pub-id pub-id-type="pmid">20737536</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muguruma</surname><given-names>Y</given-names></name><name><surname>Yahata</surname><given-names>T</given-names></name><name><surname>Warita</surname><given-names>T</given-names></name><name><surname>Hozumi</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>R</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Ando</surname><given-names>K</given-names></name></person-group><article-title>Jagged1-induced Notch activation contributes to the acquisition of bortezomib resistance in myeloma cells</article-title><source>Blood Cancer J</source><year>2017</year><volume>7</volume><issue>12</issue><fpage>650</fpage><pub-id pub-id-type="doi">10.1038/s41408-017-0001-3</pub-id><pub-id pub-id-type="pmid">29242532</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CY</given-names></name><name><surname>Chen</surname><given-names>YY</given-names></name><name><surname>Hsieh</surname><given-names>MS</given-names></name><name><surname>Ho</surname><given-names>CC</given-names></name><name><surname>Chen</surname><given-names>KY</given-names></name><name><surname>Shih</surname><given-names>JY</given-names></name><name><surname>Yu</surname><given-names>CJ</given-names></name></person-group><article-title>Expression of notch gene and its impact on survival of patients with resectable non-small cell lung cancer</article-title><source>J Cancer</source><year>2017</year><volume>8</volume><issue>7</issue><fpage>1292</fpage><lpage>1300</lpage><pub-id pub-id-type="doi">10.7150/jca.17741</pub-id><pub-id pub-id-type="pmid">28607605</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Brunskill</surname><given-names>E</given-names></name><name><surname>Varnum-Finney</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>A</given-names></name><name><surname>Jay</surname><given-names>PY</given-names></name><name><surname>Bernstein</surname><given-names>I</given-names></name><name><surname>Morimoto</surname><given-names>M</given-names></name><name><surname>Kopan</surname><given-names>R</given-names></name></person-group><article-title>The intracellular domains of Notch1 and Notch2 are functionally equivalent during development and carcinogenesis</article-title><source>Development.</source><year>2015</year><volume>142</volume><issue>14</issue><fpage>2452</fpage><lpage>2463</lpage><pub-id pub-id-type="doi">10.1242/dev.125492</pub-id><pub-id pub-id-type="pmid">26062937</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group><article-title>Downregulation of miR-153 contributes to epithelial-mesenchymal transition and tumor metastasis in human epithelial cancer</article-title><source>Carcinogenesis.</source><year>2013</year><volume>34</volume><issue>3</issue><fpage>539</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgs374</pub-id><pub-id pub-id-type="pmid">23188671</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>WJ</given-names></name><name><surname>Zhang</surname><given-names>EN</given-names></name><name><surname>Zhong</surname><given-names>ZK</given-names></name><name><surname>Jiang</surname><given-names>MZ</given-names></name><name><surname>Yang</surname><given-names>XF</given-names></name><name><surname>Zhou</surname><given-names>DM</given-names></name><name><surname>Wang</surname><given-names>XW</given-names></name></person-group><article-title>MicroRNA-153 expression and prognosis in non-small cell lung cancer</article-title><source>Int J Clin Exp Pathol</source><year>2015</year><volume>8</volume><issue>7</issue><fpage>8671</fpage><lpage>8675</lpage><pub-id pub-id-type="pmid">26339455</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapidot</surname><given-names>T</given-names></name><name><surname>Sirard</surname><given-names>C</given-names></name><name><surname>Vormoor</surname><given-names>J</given-names></name><name><surname>Murdoch</surname><given-names>B</given-names></name><name><surname>Hoang</surname><given-names>T</given-names></name><name><surname>Caceres-Cortes</surname><given-names>J</given-names></name><name><surname>Minden</surname><given-names>M</given-names></name><name><surname>Paterson</surname><given-names>B</given-names></name><name><surname>Caligiuri</surname><given-names>MA</given-names></name><name><surname>Dick</surname><given-names>JE</given-names></name></person-group><article-title>A cell initiating human acute myeloid leukaemia after transplantation into SCID mice</article-title><source>Nature.</source><year>1994</year><volume>367</volume><issue>6464</issue><fpage>645</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1038/367645a0</pub-id><pub-id pub-id-type="pmid">7509044</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawood</surname><given-names>S</given-names></name><name><surname>Austin</surname><given-names>L</given-names></name><name><surname>Cristofanilli</surname><given-names>M</given-names></name></person-group><article-title>Cancer stem cells: implications for cancer therapy</article-title><source>Oncology.</source><year>2014</year><volume>28</volume><issue>12</issue><fpage>1101</fpage><pub-id pub-id-type="pmid">25510809</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertolini</surname><given-names>G</given-names></name><name><surname>Roz</surname><given-names>L</given-names></name><name><surname>Perego</surname><given-names>P</given-names></name><name><surname>Tortoreto</surname><given-names>M</given-names></name><name><surname>Fontanella</surname><given-names>E</given-names></name><name><surname>Gatti</surname><given-names>L</given-names></name><name><surname>Pratesi</surname><given-names>G</given-names></name><name><surname>Fabbri</surname><given-names>A</given-names></name><name><surname>Andriani</surname><given-names>F</given-names></name><name><surname>Tinelli</surname><given-names>S</given-names></name><etal/></person-group><article-title>Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment</article-title><source>Proc Natl Acad Sci U S A</source><year>2009</year><volume>106</volume><issue>38</issue><fpage>16281</fpage><lpage>16286</lpage><pub-id pub-id-type="doi">10.1073/pnas.0905653106</pub-id><pub-id pub-id-type="pmid">19805294</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>JF</given-names></name><name><surname>Tan</surname><given-names>Y</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Mrsny</surname><given-names>RJ</given-names></name><name><surname>Li</surname><given-names>W</given-names></name></person-group><article-title>Cancer stem cell marker Musashi-1 rs2522137 genotype is associated with an increased risk of lung cancer</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><issue>5</issue><fpage>e95915</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0095915</pub-id><pub-id pub-id-type="pmid">24787949</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Ning</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>HS</given-names></name><name><surname>Cai</surname><given-names>SH</given-names></name><name><surname>Du</surname><given-names>J</given-names></name></person-group><article-title>Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/beta-catenin/snail signaling pathway</article-title><source>Eur J Pharmacol</source><year>2014</year><volume>723</volume><fpage>156</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2013.12.004</pub-id><pub-id pub-id-type="pmid">24333218</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Ge</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name></person-group><article-title>miR-153 inhibits the migration and the tube formation of endothelial cells by blocking the paracrine of angiopoietin 1 in breast cancer cells</article-title><source>Angiogenesis.</source><year>2018</year><volume>21</volume><issue>4</issue><fpage>849</fpage><lpage>860</lpage><pub-id pub-id-type="doi">10.1007/s10456-018-9630-9</pub-id><pub-id pub-id-type="pmid">29959560</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>Mu</surname><given-names>Y</given-names></name><name><surname>Piao</surname><given-names>H</given-names></name></person-group><article-title>MicroRNA-153-3p enhances cell radiosensitivity by targeting BCL2 in human glioma</article-title><source>Biol Res</source><year>2018</year><volume>51</volume><issue>1</issue><fpage>56</fpage><pub-id pub-id-type="doi">10.1186/s40659-018-0203-6</pub-id><pub-id pub-id-type="pmid">30537994</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Xi</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Deng</surname><given-names>Q</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Kumar</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><etal/></person-group><article-title>Correction to: miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy</article-title><source>J Hematol Oncol</source><year>2018</year><volume>11</volume><issue>1</issue><fpage>90</fpage><pub-id pub-id-type="doi">10.1186/s13045-018-0633-1</pub-id><pub-id pub-id-type="pmid">29970126</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiuza</surname><given-names>UM</given-names></name><name><surname>Arias</surname><given-names>AM</given-names></name></person-group><article-title>Cell and molecular biology of Notch</article-title><source>J Endocrinol</source><year>2007</year><volume>194</volume><issue>3</issue><fpage>459</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1677/JOE-07-0242</pub-id><pub-id pub-id-type="pmid">17761886</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>NOTCH1 signaling regulates self-renewal and platinum chemoresistance of cancer stem-like cells in human non-small cell lung cancer</article-title><source>Cancer Res</source><year>2017</year><volume>77</volume><issue>11</issue><fpage>3082</fpage><lpage>3091</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-1633</pub-id><pub-id pub-id-type="pmid">28416482</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>SJ</given-names></name></person-group><article-title>Notch signalling: a simple pathway becomes complex</article-title><source>Nat Rev Mol Cell Biol</source><year>2006</year><volume>7</volume><issue>9</issue><fpage>678</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1038/nrm2009</pub-id><pub-id pub-id-type="pmid">16921404</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>WH</given-names></name><name><surname>Ho</surname><given-names>BC</given-names></name><name><surname>Hsiao</surname><given-names>YJ</given-names></name><name><surname>Chen</surname><given-names>JS</given-names></name><name><surname>Yeh</surname><given-names>CH</given-names></name><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Chang</surname><given-names>GC</given-names></name><name><surname>Su</surname><given-names>KY</given-names></name><name><surname>Yu</surname><given-names>SL</given-names></name></person-group><article-title>JAG1 is associated with poor survival through inducing metastasis in lung cancer</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><issue>3</issue><fpage>e0150355</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0150355</pub-id><pub-id pub-id-type="pmid">26930648</pub-id></element-citation></ref></ref-list></back></article>